Meeting Banner
Abstract #0719

The GRAPH-CRAFITY Score: a novel prognostic tool for patients with hepatocellular carcinoma treated with targeted therapy and immunotherapy

Ying Xu1, Lu Li1, Yi Yang1, Lizhi Xie2, Sicong Wang2, Feng Ye1, and Xinming Zhao1
1Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China, 2GE Healthcare, China, Beijing, China

Synopsis

Keywords: Liver, Treatment, Targeted Therapy, Immunotherapy, Prognostic Prediction ·One-hundred and sixty-six patients (55.6±10.4 years) treated with lenvatinib plus anti-PD-1 antibody were included in training cohort and 77 patients (55.4±10.7 years) treated with lenvatinib or bevacizumab plus anti-PD-1 antibody were included in validation cohort. Based on independent risk factors (Gender, intRatumoral fAt, enhancing tumor caPsule, gross growtH type and CRAFITY Score) identified by the multivariate analysis, a novel prognostic tool named GRAPH-CRAFITY Score was developed to predict OS. GRAPH-CRAFITY Score by integrating Gender, MR features and laboratory tests is an effective and user-friendly tool to predict OS of HCC patients treated with targeted therapy and immunotherapy.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.

Keywords